sserted against us; our ability to obtain and enforce timely
patent and other intellectual property protection for our technology and
products; the ability to enter into, and to maintain, corporate alliances
relating to the development and commercialization of our technology and
products; market acceptance of our technology and products; our ability to
successfully manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to continue
to integrate into our business the operations of American Medical
Instruments Holdings, Inc. and our ability to achieve the operational and
other synergies and the other commercial or financial benefits expected as
a result of that acquisition; and any other factors referenced in our
annual information form and other filings with the applicable Canadian
securities regulatory authorities or the SEC.
Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
We disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained in this prospectus to reflect future results, events
Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc.
(C)2007 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
CONTACT: Jodi Regts,
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. Medical College receives $377K to study brain disease2
. Lucigen receives $750K grant to boost biofuel yields3
. Medical College receives $1.4M cancer grant4
. Wisconsin biotech firm receives $107K NIH grant5
. InvivoSciences receives NIH grant for heart technology6
. Medical College receives $11 million grant to study high blood pressure7
. Madison business receives $115,000 of new state biofuels funding8
. Superior receives funds for technical training9
. UWM receives state funding for plastics research10
. GEs Centricity EHR receives federal certification11
. WHIE receives state eHealth Initiative contract